Showing results (91-100 of 151) with videos related to
Sort By:
Pageof 16
Cell Reports. Medicine|April 16, 2025
Evolution of the tumor immune landscape during treatment with tebentafusp, a T cell receptor-CD3 bispecificJoseph J Sacco, Peter Kirk, Emma Leach, et al.Cancer Research Communications|March 2, 2023
Integrated, Longitudinal Analysis of Cell-free DNA in Uveal MelanomaDerek Wong, Ping Luo, Nadia Znassi, et al.Cancer Immunology, Immunotherapy : CII|February 13, 2019
Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2Linh T Nguyen, Samuel D Saibil, Valentin Sotov, et al.Cell Reports|August 28, 2025
T cell receptor repertoire in cell-free DNA as a proxy for tumor infiltrates in patients treated with pembrolizumabShirin Soleimani, Xuan Li, Ben X Wang, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 2, 2021
Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing SchedulesGeorgina V Long, Caroline Robert, Marcus O Butler, et al.Cancer|February 16, 2019
Hyperprogressive disease in early-phase immunotherapy trials: Clinical predictors and association with immune-related toxicitiesYada Kanjanapan, Daphne Day, Lisa Wang, et al.Journal for Immunotherapy of Cancer|June 6, 2024
Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanomaJoseph J Sacco, Richard D Carvajal, Marcus O Butler, et al.American Journal of Clinical Dermatology|October 8, 2024
Pembrolizumab for the First-Line Treatment of Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma: Results from the Single-Arm, Open-Label, Phase III KEYNOTE-913 StudyLaurent Mortier, Lisa Villabona, Ben Lawrence, et al.Translational Oncology|August 24, 2025
Elucidating divergent biology in uterine carcinosarcomaVikas Garg, Stephenie D Prokopec, Simone C Stone, et al.Journal for Immunotherapy of Cancer|March 18, 2020
A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumorsAung Naing, Justin F Gainor, Hans Gelderblom, et al.Pageof 16